Skip to content
20-F

Annual Report (Foreign)

Universe Pharmaceuticals INC UPC

0001213900-26-009000

← back to feed
Filed
Jan 29, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Sep 30, 2025 455.87K sh
Shares Diluted FY 2025 · Sep 30, 2024 13.92K sh
Shares Diluted restated FY 2025 · Sep 30, 2023 6.04K sh
Shares Outstanding FY 2025 · Sep 30, 2025 563.34K sh
Capex FY 2025 · Sep 30, 2025 $266.77M
Capex restated FY 2025 · Sep 30, 2024 $208.32M
Capex restated FY 2025 · Sep 30, 2023 $44.17M
Operating Cash Flow FY 2025 · Sep 30, 2025 −$5.05B
Operating Cash Flow restated FY 2025 · Sep 30, 2024 −$9.51B
Operating Cash Flow restated FY 2025 · Sep 30, 2023 $1.12B
Short Term Debt FY 2025 · Sep 30, 2025 $7.15B
Short Term Debt restated FY 2025 · Sep 30, 2024 $5.86B
Stockholders Equity FY 2025 · Sep 30, 2025 $56.13B
Stockholders Equity restated FY 2025 · Sep 30, 2024 $45.5B
Stockholders Equity restated FY 2025 · Sep 30, 2023 $27.97B
Stockholders Equity restated FY 2025 · Sep 30, 2022 $35.33B
Current Liabilities FY 2025 · Sep 30, 2025 $13.17B
Current Liabilities restated FY 2025 · Sep 30, 2024 $20.31B
Total Liabilities FY 2025 · Sep 30, 2025 $13.17B
Total Liabilities restated FY 2025 · Sep 30, 2024 $22.45B
Current Assets FY 2025 · Sep 30, 2025 $53.6B
Current Assets restated FY 2025 · Sep 30, 2024 $51.64B
Total Assets FY 2025 · Sep 30, 2025 $69.3B
Total Assets restated FY 2025 · Sep 30, 2024 $67.95B
Eps Diluted FY 2025 · Sep 30, 2025 −$8.06
Eps Diluted FY 2025 · Sep 30, 2024 −$626.96
Eps Diluted restated FY 2025 · Sep 30, 2023 −$1,089.21
Eps Basic FY 2025 · Sep 30, 2025 −$8.06
Eps Basic FY 2025 · Sep 30, 2024 −$626.96
Eps Basic restated FY 2025 · Sep 30, 2023 −$1,089.21
Sga Expense FY 2025 · Sep 30, 2025 $3.75B
Sga Expense restated FY 2025 · Sep 30, 2024 $2.89B
Sga Expense restated FY 2025 · Sep 30, 2023 $2.64B
Rd Expense FY 2025 · Sep 30, 2025 $671.76M
Rd Expense restated FY 2025 · Sep 30, 2024 $3.03B
Rd Expense restated FY 2025 · Sep 30, 2023 $4.86B
Net Income FY 2025 · Sep 30, 2025 −$3.67B
Net Income restated FY 2025 · Sep 30, 2024 −$8.73B
Net Income restated FY 2025 · Sep 30, 2023 −$6.58B
Operating Income FY 2025 · Sep 30, 2025 −$2.92B
Operating Income restated FY 2025 · Sep 30, 2024 −$8.02B
Operating Income restated FY 2025 · Sep 30, 2023 −$3.97B
Gross Profit FY 2025 · Sep 30, 2025 $6.3B
Gross Profit restated FY 2025 · Sep 30, 2024 $6.07B
Gross Profit restated FY 2025 · Sep 30, 2023 $10.32B
Cost Of Revenue FY 2025 · Sep 30, 2025 $11.56B
Cost Of Revenue restated FY 2025 · Sep 30, 2024 $16.95B
Cost Of Revenue restated FY 2025 · Sep 30, 2023 $21.99B
Revenue FY 2025 · Sep 30, 2025 $17.86B
Revenue restated FY 2025 · Sep 30, 2024 $23.02B
Revenue restated FY 2025 · Sep 30, 2023 $32.31B